对FH缺陷细胞癌的综合分子分析识别了分子亚型和潜在的治疗点
Xingming Zhang1, Junjie Zhao1, Xiaoxue Yin2
1Department of Urology, Institute of Urology, Sichuan Clinical Research Center for kidney and urologic diseases, West China Hospital, Sichuan University, Chengdu, China.
Nature communications
|May 12, 2025
概括
富马酸酸酶缺乏的细胞癌 (FH缺乏的RCC) 是积极的. 综合基因组研究确定了具有明显治疗反应的三种亚型,为这种致命的癌指导精准医学.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 富马酸酸酶缺乏的细胞癌 (FH缺乏的RCC) 是一种罕见且极具致命性的癌亚型.
- 了解它的分子基础对于开发有效的治疗策略至关重要.
研究的目的:
- 进行FH缺乏RCC的全面综合基因组研究.
- 确定分子亚型及其与瘤异质性和甲基化模式的关联.
- 根据分子特征预测治疗反应.
主要方法:
- 对FH缺乏RCC的综合基因组分析.
- 开发一种CpG特定位点的甲基化特征,用于FH缺乏RCC的识别.
- 转录组分析以定义基于路径丰富的分子亚型.
主要成果:
- 根据路径丰富 (免疫/血管性/突风性,WNT/突出/MAPK,增殖/茎状) 确定了三种不同的分子亚型 (C1,C2,C3).
- 亚型C1显示了免疫检查点阻塞 (ICB) 和抗血管生成疗法联合的显著生存益处.
- 亚型C2和C3对这些疗法呈现出不同的反应,C3对抗血管性单一治疗和与ICB结合的抗血管性单一治疗呈现不良结果.
结论:
- 缺乏FH的RCC表现出显著的分子异质性.
- 不同的亚型与免疫疗法和抗血管生成治疗的不同反应相关.
- 这些发现为精准医学方法提供了基础,用于管理FH缺乏RCC.
更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.2K
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.5K
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
